Intuitive Surgical's operating leverage stands out among medical device manufacturers, with systematic screening highlighting a net margin of 28.45% and operating margin of 31.28%, metrics that position the company in the upper quartile for healthcare sector profitability. The current market capitalization of $124.8 billion reflects the company's dominant position in robotic-assisted surgical systems, though the share price at $353.33 represents a 41.5% decline from the 52-week high of $603.88, creating a notable valuation reset from 2024 peak levels.

The fundamental model indicates several distinctive characteristics:

• Revenue growth of 20.66% year-over-year combined with EPS expansion of 21.76% demonstrates consistent procedural volume growth and pricing power
• Return on equity of 17.81% and return on assets of 15.54% exceed typical medical device benchmarks, supported by zero debt (D/E ratio 0.0)
• Price-to-sales ratio of 11.29 and P/E of 39.69 reflect premium valuations relative to diversified peers ABT and SYK, justified by the company's recurring revenue model from instruments and accessories
• Current ratio of 4.87 signals exceptional liquidity management, providing operational flexibility for continued R&D investment

Risk factors include elevated beta of 1.47, indicating above-market volatility sensitivity, and the absence of reported free cash flow per share data in this dataset limits complete working capital assessment. The price-to-book ratio of 11.26 suggests the market assigns substantial intangible value to the installed base and switching costs. Against peers, ISRG trades at a significant premium based on specialized technology moat rather than product diversification, distinguishing its risk-return profile from broader device manufacturers.